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Dear Editor,  
Please find enclosed the manuscript entitled “In vitro and in vivo characterization of stem-
like cells from canine osteosarcoma and assessment of drug sensitivity” by M. Gatti et al., we 
would like to submit for publication in Experimental Cell Research.  
We certify that this manuscript contains original work and that it has not been published or 
submitted for publication elsewhere. All authors have read and agreed to the content of the 
manuscript and declare that they have no competing interests. 
In this paper we investigated the possibility of isolating, expanding and characterizing 
tumorigenic cancer stem cells from three canine osteosarcoma primary cultures.  
We characterized these cells for phenotypic and functional features, as the ability to grow 
as non-adherent sarcospheres in a growth factor containing medium, the expression profile for 
stem- and tumor-related markers, the self-renewal ability, and the tumorigenic potential in vivo. In 
parallel, the expression profile for relevant antigens, as staining intensity and distribution, has been 
analyzed in a series of canine osteosarcoma tissues, including those from which cultures were 
derived, and we compared the patterns of expression with tumors originated by sarcosphere-
derived cells in mice verifying that xenografts recapitulate the histology and are phenotypically 
identical to the original canine osteosarcoma. Osteosarcoma cancer stem cell are able to long-term 
proliferate in vitro and thei retain tumor-forming potential during serial in vivo transplantation. 
In vitro differentiation analysis revealed that osteosarcoma cancer stem cells possess a 
mesenchymal-like ability to differentiate into adipogenic, osteogenic and chondrogenic lineages. 
In addition, a distinctive sensitivity to standard first-line drugs for osteosarcoma, doxorubicin 
and cisplatin, was observed in both CSC-enriched and parental primary cultures. Moreover, 
metformin, a type-2 diabetes drug, alone or in combination, affects cell viability and self-renewal, 
and might be effective therapeutic strategy to eradicate osteosarcoma cancer stem cells. 
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Thus, the impact of the present manuscript is the feasibility of methodologies that allows 
establishment of long-term cancer stem cells from canine osteosarcoma as observed in human 
counterpart. Likewise, the possibility to detect the tumorigenic cell population in neoplasms of 
companion animals, may represent a reliable experimental model to assay drug efficacy, and 
innovative therapeutic strategy to eradicate osteosarcoma stem cells, to be exploited in human 
setting.  
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Research, we look forward to hearing from you. 
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ABSTRACT  
Osteosarcoma is an aggressive bone tumor which displays biological and molecular heterogeneity, largely 
dependent on cancer stem cells (CSCs). CSC self-renewing and drug resistance cause treatment failure and 
tumor recurrence. CSC identification of in osteosarcoma and their efficient targeting are still open questions. 
Spontaneous canine osteosarcoma shares clinical and biological features with the human tumor, 
representing a model for translational studies. Here we enriched in CSCs three canine osteosarcoma 
cultures. These CSC cultures grow, in serum-free conditions, as anchorage-independent spheroids, show 
mesenchymal-like properties and in vivo tumorigenicity, recapitulating the heterogeneity of the original 
osteosarcoma. Osteosarcoma CSCs express stem-related factors (Sox2, Oct4, CD133) and chemokine 
receptors and ligands (CXCR4, CXCL12) involved in tumor proliferation and self-renewal. Standard drugs for 
osteosarcoma treatment (doxorubicin and cisplatin) affected CSC-enriched and parental primary cultures, 
showing different efficacy within tumors. Moreover, metformin, a type-2 diabetes drug, significantly inhibits 
osteosarcoma CSC viability and self-renewal, and in co-treatment with doxorubicin and cisplatin enhances 
drug cytotoxicity. Collectively, we demonstrate that canine osteosarcoma primary cultures contain CSCs 
exhibiting distinctive sensitivity to anticancer agents, as a reliable experimental model to assay drug efficacy. 
We also provide proof-of-principle of metformin, alone or in combination, efficacy as pharmacological 
strategy to target osteosarcoma CSCs. 
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OSA, osteosarcoma; CSCs, cancer stem cells; CXCR4, C-X-C motif chemokine receptor 4;CXCL12, C-X-C motif 
chemokine ligand 12; CD117, KIT proto-oncogene receptor tyrosine kinase; STAT3, signal transducer and 
activator of transcription 3; Oct4, POU class 5 homeobox 1; Sox2, SRY-box 2¸CI, combination index; CFE, 
colony formation efficiency; DAPI, 4,6-diamidino-2-phenylindole dihydrochloride; MTT, (3-(4,5-
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fibroblast growth factor; H&E, hematoxylin and eosin staining. 
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1. INTRODUCTION 
Osteosarcoma (OSA) is the most common primary bone malignancy in young people, predominantly 
occurring in long bones, in areas characterized by proliferating cells and active bone growth [1]. OSA is 
classified into different histopathologic subtypes (e.g. osteoblastic, fibroblastic, chondroblastic), which, 
however, have not prognostic or therapeutic relevance [2, 3]. Despite the relative low incidence, OSA 
accounts for high morbidity and mortality. The therapy of these tumors is extremely complex [4] and the 
outcome influenced by several factors such as tumor and metastasis site, presence of undetectable micro-
metastases at diagnosis (in more than 80% of patients), extent of lesion and feasibility of complete surgical 
resection [5]. Neo-adjuvant chemotherapy for localized OSA includes methotrexate, doxorubicin, and 
cisplatin (MAP), followed by surgery and adjuvant therapy (doxorubicin) to eliminate micro-metastases [6, 
7]. Patients bearing localized OSA, and treated with MAP regimen, reach more than 50% overall survival at 5 
years, which however did not improve in the last decades [8]; up to 30% of patients with newly diagnosed 
OSA have already metastatic spread, commonly in the lungs, making the treatment challenging and survival 
expectancy very poor (5-year survival of about 20%) [9]. No new chemotherapeutic drugs demonstrate 
effectiveness in resistant or relapsed OSA (pulmonary recurrence occurs in about 30% of patients) for which 
no standard second-line strategies are available; thus intense investigations are currently needed to identify 
both innovative agents active in this disease and cellular/molecular mechanisms that sustain OSA cell 
resistance and recurrence. 
Different drug resistance mechanisms have been observed in OSA: impairment of drug cellular uptake, 
enhanced DNA repair system activity, evasion of apoptosis, adaptive signaling from tumor 
microenvironment, and the presence of cancer stem cells (CSCs) [10]. OSA, as other solid tumors, is cellularly 
heterogeneous, containing hierarchically organized cells, sustained by CSCs, acting as tumor-initiating cells. 
CSCs are a tumorigenic cell subset with intrinsic drug resistance, able to persist in the tumor mass by self-
renew and to differentiate into non-tumorigenic cell populations composing the bulk of the tumor [11, 12]. 
In OSA, several cell types have been proposed as stem-like population, including committed osteo-
progenitors or undifferentiated mesenchymal stem cells (MSCs), carrying genetic and/or epigenetic 
alterations [13-15], which enable these cells to escape the control of proliferation and to differentiate into 
mature bone-forming osteoblasts [16]. Self-renewal properties of CSCs, which allow the isolation and 
enrichment in vitro of this cell subset, are evaluated by the formation of tumor spheres under non-adherent 
and serum-free culture conditions [17] while, in vivo, tumorigenicity of putative CSCs can be assayed by 
serial transplantation into immunocompromised mice [18]. Beside functional assays, the evaluation of stem 
markers, such as CD133, CD117, Sox2 and Oct4, was also proposed to identify CSCs, being claimed as 
possible specific marker candidates [19-21]; however, a definite phenotype to precisely identify tumor stem-
like cells is still lacking in OSA [12] as well as in other cancers. Importantly, cell populations endowed with 
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stem-like properties were isolated from several pet tumors including canine and feline mammary 
carcinomas, canine prostate and hepatocellular carcinomas, and OSAs, among others [22-30] representing a 
high translational value model for human tumors. In particular, naturally occurring OSA is the most common 
primary bone tumor in adult dogs and represents an excellent model for the human disease, sharing similar 
biological and clinical behavior (invasiveness and spreading to lungs, poor median survival time, frequent 
metastatic disease) [31-33]. In oncology, the dog model of spontaneous OSA, due to its development in a 
shorter time than in humans, allowed relevant studies on genomics, diagnosis and drug sensitivity [31]. 
Moreover, genomic (e.g. TP53, RB1 alterations) and molecular features (dysregulated expression of Met and 
STAT3, and the chemokine receptor CXCR4, proposed as putative prognostic markers or indicators of 
metastatic disease) of canine OSAs closely resemble the human disease [34]. Furthermore, the same current 
therapeutic strategies are used in both humans and dogs, and the new drugs under study are proposed to 
represent valuable approaches for both kind of patients [31, 35].  
Both human and canine OSAs contain CSCs that grow in anchorage-independent conditions as sarcospheres 
and possess tumor-initiating properties, expressing common putative CSC-related markers and stem-like 
signatures [30, 36-38].  
Therefore, understanding the heterogeneous biology of OSA, likely driven by CSCs, is important to elucidate 
its pathogenesis and therapeutic response, representing the critical target for treatments eliciting tumor 
growth arrest and avoiding relapses.  
Several in vitro studies report the antiproliferative efficacy of repurposed drugs against CSCs from different 
tumor types [39, 40]. In particular, metformin, an oral biguanide commonly used as first-line treatment for 
type 2 diabetes, selectively affects CSC viability in several human tumors [41-48]. Metformin inhibits OSA cell 
proliferation, invasiveness, and self-renewal [49], and sensitizes OSA CSCs to cisplatin [50, 51]. However, in 
these studies CSC-like cells were mainly derived from continuous cell lines grown in the presence of high 
fetal bovine serum, an experimental conditions causing the loss of original CSC biological features [52]. To 
overcome this problem, in this study we performed phenotypic and in vitro and in vivo functional 
characterization of three primary cultures enriched with tumorigenic CSCs, derived from canine OSAs. Using 
this model, we investigated the cytotoxic activity of anticancer drugs (cisplatin, doxorubicin) commonly used 
for OSA treatment, comparing the sensitivity of OSA CSCs and the respective non-stem cell counterparts. In 
addition, we studied the efficacy of metformin on OSA CSC viability and self-renewal, and the effects 
achievable by combined treatment with standard drugs and metformin.  
 
2. MATERIALS AND METHODS 
2.1. Primary cell cultures of canine OSA and cancer stem cell (CSC) enrichment 
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Three primary canine OSA cell cultures, named OSA1, OSA2 and OSA3, were isolated from post-surgical 
tumor specimens at the Department of Animal Pathology of the University of Torino [53]. OSA1 cells derived 
from osteoblastic productive grade III OSA, while OSA2 and OSA3 cells derived from chondroblastic grade III 
OSAs. The osteoblastic origin of the cultured cells was assessed by morphological observation and alkaline 
phosphatase activity [53]. Cells were cultured in Iscove's Modified Dulbecco's Medium (IMDM, GIBCO®),) 
supplemented with 10% fetal bovine serum (FBS, EuroClone), penicillin/streptomycin (EuroClone) and 
maintained at 37°C in a humidified atmosphere with 5% CO2. 
Enrichment of OSA primary cultures with stem-like cell subpopulation was performed exploiting their low 
attachment to tissue culture plastic when cultured in “stem cell medium” containing IMDM, 1% FBS, N2-
supplement (100X, GIBCO®), epidermal growth factor (EGF, 10 ng/ml, Miltenyi Biotec) and basic fibroblast 
growth factor (bFGF, 10 ng/ml, Miltenyi Biotec) [38, 54]. This in vitro procedure allows the selection of tumor 
cells displaying defining stem cell properties of self-renewal and differentiation as prospectively identifiable 
subpopulations of tumor cells. CSCs from OSA1 and OSA2 have been already partially characterized in vitro 
in a previous study [30], while the third one (OSA3) has been used to select putative CSCs for the first time. 
2.2. Sarcosphere formation assay 
Single cell suspensions of primary cultures were seeded in 6-well ultra-low attachment plates (Corning) at a 
density of 6X104 cells/well in stem cell medium. After 7 days of incubation, primary spheres (sarcospheres) 
were obtained. The persistence of self-renewal after long-lasting in vitro culturing was shown by 
dissociating primary spheres to single cells, which were allowed to generate secondary sarcospheres under 
the same culture conditions. Serial passaging of first generation spheres, was performed every 7 days of 
incubation, harvesting the spheres by centrifugation, and dissociation of the pellet to single cells using 
TrypLE Express Enzyme (GIBCO®), and then expanding them again. To test the effect of metformin on 
sphere growth, after 7 days of culture to allow sphere generation, sarcospheres were treated with 3 mM 
metformin and counted after 5 days. Only spheres with at least 40-50 µm were considered. To further 
demonstrate the activity of metformin, sphere-formation capacity was monitored in the absence or 
presence of the drug (3 mM): every 7 days sarcospheres formed were disaggregated, cells were counted and 
re-plated in fresh medium in the same conditions (in the presence of vehicle or metformin). The number of 
viable cells was evaluated at every passage.  
2.3. Immunohistochemistry (IHC) 
IHC was performed on 4-μm sections of formalin-fixed paraffin-embedded tissue derived from 12 OSA (9 
males and 3 females with mean age 7.7 years, range 0.5-14). As previously described [55], 
deparaffinized/rehydrated sections were incubated in citrate-antigen retrieval buffer, nonspecific 
immunoreactivity was blocked with 10% normal goat serum (Sigma-Aldrich) and primary antibodies applied 
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overnight at 4 °C. The following antibodies were used: Oct4 (Abcam), CXCR4 (Sigma-Aldrich), CXCL12 
(Abcam), CD117 and STAT3 (SantaCruz). Real Envision Detection System Peroxidase/DAB+, mouse/rabbit 
(Dako) was used for the detection according to the manufacturer's instructions. Counterstaining with 
hematoxylin was performed. For each staining, a negative control, was included without the primary 
antibody or with rabbit/mouse IgG. Images were captured using a Nikon Coolscope microscope. The 
intensity of immunoreaction and the percentage of positive cells were evaluated, and a score ranging from 0 
to 3 was assigned (0 = negative, 1 = low positivity, 2 = positivity, 3 = high positivity), independently by two 
pathologists (A.R. and C.C.). 
 
2.4. Immunofluorescence (IF) 
OSA spheres growing on glass coverslips were fixed with 4% paraformaldehyde, permeabilized with 0.1% 
Triton X-100 in PBS, and blocked with NGS (all from Sigma-Aldrich) before adding the following primary 
antibodies: Oct4 and CXCL12 (AbCam), CXCR4 (Sigma-Aldrich), osterix (Santa Cruz Biotechnologies), type I 
collagen (SP1.D8) and osteonectin (AON-1) from Developmental Studies Hybridoma Bank, vimentin (Dako), 
and Sox2 (Millipore), all diluted 1:100, and CD133 (Milteny Biotec) diluted 1:10, at r.t for 1 h. Fluorochrome-
conjugated secondary antibodies (goat anti-mouse and anti-rabbit Alexa Fluor-568 or Alexa Fluor-488, 
Molecular Probes) were applied, and nuclei were counterstained with DAPI (Sigma-Aldrich) [56]. Negative 
controls omitting primary antibodies were included in all the experiments. Coverslips were mounted with 
Mowiol (Sigma-Aldrich) and images were obtained with a DM2500 microscope equipped with a DFC350FX 
digital camera (Leica Microsystems). 
 
2.5. In vitro multilineage differentiation analysis 
To study the ability of cells from sarcospheres to differentiate into adipogenic, osteogenic and chondrogenic 
lineages and verify the enrichment of OSA primary cultures with stem-like cell subpopulation, differentiation 
analyses were performed. First, to assess the ability to differentiate into non-stem tumor cells, sarcospheres 
were collected, dissociated into single cells, shifted to IMDM+10%FBS (without growth factors) and cultured 
for at least 10 days [18, 57]. 
To differentiate OSA CSCs towards mesenchymal lineages (osteoblast, chondrocyte and adipocyte), 
sarcospheres were disaggregated into single-cell suspension and induced to phenotype change using the 
StemPro® differentiation kits (GIBCO®) according to the manufacturer’s instructions. Cells were seeded into 
StemPro® Adipogenesis Differentiation medium (GIBCO®) for 21 days, replacing medium every 3 days. 
Adipogenesis was using Oil Red O (Sigma-Aldrich) staining to detect intracellular lipid vacuoles. Osteogenic 
differentiation was assessed after 10 days of incubation in StemPro® Osteogenesis differentiation medium 
(GIBCO®) by 2% alizarin red S (Sigma-Aldrich) staining to detect the formation of calcium deposits. 
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Chondrogenic differentiation was monitored after 20 days in StemPro® Chondrogenic differentiation 
medium (GIBCO®) by staining cultures with 1% Alcian Blue (Sigma-Aldrich) for proteoglycan matrix 
production. 
 
2.6. Tumorigenicity 
All animal procedures were carried out under project license in compliance with guidelines approved by 
Ethical Committee for animal use in cancer research at IRCCS-AOU San Martino-IST (Genova, Italy) and 
Italian Ministry of Health (n° 327, Dl.vo 116/92 and 412, in accordance with EU Directive 2010/63/EU). Four 
NOD-SCID mice (Charles River) aged 6–8 weeks were used to test their ability to grow in vivo. Xenografts 
were established by pseudo-orthotopic inoculation of 1.5x105 OSA1, OSA2 and OSA3 cells re-suspended in 
100 μl Matrigel™ (BD Bioscience) and 100 μl medium, derived either from cells selected in by growing in 
stem cell medium and cultured as sarcospheres or the respective parental primary cells. Mice were 
monitored for disease symptoms and sacrificed by CO2 asphyxiation when weight loss or any other sign of 
suffering was observed. Excised tumors were divided in two parts: one was fixed in 10% buffered formalin 
and embedded in paraffin for IHC analysis, the second was cut into small fragments, and cell suspension was 
collected for in vitro culture. Tumor-derived single cells forming spheres were re-injected into new recipient 
mice to verify tumor-forming ability upon serial transplantation.  
 
2.7. MTT assay  
Cells (4,000/well) were plated into 96-well plates, allowed to attach for 24h, and treated with 1-30 mM 
metformin, 0.03-30 μM doxorubicin and 0.3-30 μM cisplatin, for 48h. All drugs were dissolved in sterile 
water and purchased from Sigma-Aldrich. Mitochondrial activity, as index of cell viability, was evaluated by 
incubation with MTT (Sigma-Aldrich, stock solution 2 mg/ml) for 2h, formazan crystals were dissolved in 
DMSO and absorbance spectrophotometrically measured at 570 nm [58]. IC50 values were calculated using 
nonlinear regression curve fit analysis selecting the log (drug) vs. response-variable slope (three parameters) 
using Prism 5.02 (GraphPad San Diego CA, USA). Each treatment was analyzed in quadruplicate, and the 
experiments were repeated at least three times. 
 
2.8. Colony formation assay  
Viable single cells were plated in 100mm dishes at a density of 450 cells/dish in IMDM+10% FBS medium in 
the presence or absence of metformin, and allowed to grow for 2 weeks monitoring colony formation [59]. 
Colonies were fixed and visualized by May-Grunewald Giemsa staining (Sigma-Aldrich). Colony formation 
efficiency (CFE %) was calculated as (number of colonies per dish/number of cells seeded per dish) × 100. 
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2.9. Statistical analysis 
All experiments were repeated at least three times. Data from quantitative experiments are expressed as 
mean ± s.e.m. Statistical significance between groups was assessed by t-test (unpaired, two-tailed) or one-
way ANOVA using Prism 5.02. Statistical significance was established at p values <0.05. For the evaluation of 
drug interaction, data form MTT assay (as described above) using doxorubicin or cisplatin alone or in 
combination with metformin, were analyzed using the median-effect method [60] and expressed as the 
combination index (CI) calculated using CompuSyn software (ComboSyn Inc., Paramus, NJ, USA) where CI<1, 
=1, and >1 indicates synergism, additive effect and antagonism, respectively. Based on CI, synergy is further 
refined as moderate synergism (combination index = 0.7-0.9), synergism (combination index = 0.3-0.7), 
strong synergism (combination index = 0.1-0.3), and very strong synergism (combination index < 0.1) [61, 
62]. 
  
3. RESULTS 
3.1. Isolation and in vitro expansion of cancer stem-like cells from canine osteosarcoma 
Three primary cell cultures were derived from one osteoblastic productive OSA grade III (OSA1), and two 
chondroblastic OSAs grade III (OSA2 and OSA3) [53]. All cultures were able to proliferate as adherent 
monolayers in FBS-containing medium (Figure 1A); however, when cultured as single cell suspension in low 
serum concentration (1% FBS) supplemented with EGF and bFGF, two growth factors required for the in vitro 
expansion of normal and cancer stem cells [54], OCS cells formed within 7-10 days non-adherent, multi-
cellular spheroids (sarcospheres) (Figure 1B). Tumor spheroids showed different morphology: OSA1 formed 
spherical, compact aggregates, while OSA2 and OSA3 generated less dense and uniform shape and circular 
spheres (Figure 1C). In growth factor-supplemented medium, sarcosphere cells were able to proliferate and 
survive for long term. Moreover, in these culture conditions OSA cells are able to generate secondary 
sarcospheres after dissociation, and re-formation passages could be repeated several times (data not 
shown). This selection allowed the in vitro expansion of an OSA cell subpopulation with morphological and 
biological characteristics different from the original cell cultures and, being in vitro spherogenic activity 
considered an indirect index of self-renewal ability, we named these cell subpopulations as OSA1 CSC, OSA2 
CSC, and OSA3 CSC (see below for the complete characterization).  
3.2. Osteosarcoma CSC spheres express osteogenic markers 
To test whether OSA CSCs within sarcospheres retain osteogenic potential, we characterized their 
phenotype by IF for bone-specific markers (Figure 1D). Osterix, one of the early osteogenic transcription 
factors and vimentin, a constituent of the intermediate filament protein family and typically a mesenchymal 
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cell marker, were expressed by almost all cells within spheres of the three OSA CSCs. Osteogenic 
differentiation was explored by detection of late osteogenic lineage proteins such as collagen type I and 
osteonectin that showed a non-homogeneous staining pattern: in particular, OSA 1 and OSA 2 CSC spheres 
contained few scattered type I collagen positive-cells and were negative for osteonectin, contrarily OSA3 
CSCs were almost negative for type I collagen and osteonectin-positive (Figure 1D). These results indicate 
that OSA1, OSA2 and OSA 3 spheres contained stem-like cells committed to osteogenic differentiation 
(maturation), although a complete differentiation was still not detectable (as demonstrated by the low levels 
of bone extracellular matrix gene osteonectin, and type I collagen). 
 
3.3. Osteosarcoma CSC spheres express stemness markers 
Being CSC pluripotency associated with the ability to maintain the expression of specific proteins and 
transcription factors, to further characterize the putative stem-like phenotype of sarcosphere cells, by IF we 
analyzed the expression of Sox2 and Oct4, two intracellular transcription factors overexpressed by stem 
cells, and CD133, a stem-cell surface marker, (Figure 2). OSA1, OSA2 and OSA3 CSC express, although not 
homogeneously, all the above mentioned markers, thus indicating the prevalence of cells with stem-like 
phenotype within spheroids (Figure 2). In addition, we tested the immunoreactivity for the chemokine 
receptor CXCR4 and its ligand CXCL12, both overexpressed in several human [63-65] and canine tumors [55] 
including bone sarcomas, and contributing to CSC maintenance, migration, and homing in metastatic sites 
[66]. IF analysis revealed that both proteins are expressed in the majority of sarcosphere cells (although 
CXCL12 was detected in less OSA2 cells) (Figure 2) confirming the relevance of the CXCL12/CXCR4 axis in OSA 
likely involved in the control and/or modulation of cell stemness. Overall, these analyses corroborated the 
stem cell properties of the spherogenic cells derived from all canine OSA cultures.  
3.4. In vitro differentiation capacity of osteosarcoma sphere cells  
Since serum depletion promotes CSC-like phenotype, we tested whether this process was reversible by 
shifting sarcosphere-derived single cells from OSA1, OSA2 and OSA3 CSCs to the original culture condition, in 
serum-containing medium. After 10-15 days, CSCs lost anchorage-independent proliferation, grew as 
monolayers (Figure 3), and re-acquired the morphology and shape resembling parental primary OSA cultures 
(see Figure 1), likely suggesting that OSA sarcospheres harbor stem-like cells able to in vitro (re-
)differentiate. 
Next, based on the recent evidence suggesting that the cell-of-origin in OSA most likely derives from 
mesenchymal stem cells, the precursor of osteoblasts, rather than osteoblast-committed cells [13], to 
explore the differentiation potential of sarcosphere cells, we induced our cultures to differentiate along 
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mesenchymal lineages. Therefore, the putative mesenchymal origin of OSA CSCs should grant this cell subset 
the ability to differentiate into osteocytes, chondrocytes, and adypocytes. 
We evaluated the potential of OSA1, OSA2 and OSA3 CSCs to undergo tri-lineage differentiation by culturing 
them in specific standardized differentiation media (Figure 3). Foci of mineralization were visualized by 
Alizarin Red staining in osteogenic-cultured conditions after 21 days in all three OSA CSCs, although at 
different level: OSA1 CSC formed a stronger deposited mineralized matrix, detectable by more consistent 
staining than OSA2 and OSA3 cultures (Figure 3). Chondrogenic differentiation was demonstrated from 
Alcian Blue staining after 21 days in chondrogenic medium: OSA1 and OSA2 CSCs showed solid proteoglycan 
deposits as index of chondroblastic matrix, while OSA3 CSCs scarcely grew in this culture conditions and 
differentiation was less evident (Figure 3). After 14 days of adipogenic differentiation, OSA1 CSC were 
stained with Oil Red and showed several visible intracellular vacuoles containing lipid drops in most of the 
cells, whereas in OSA2 and OSA3 CSCs only few cells survived the treatment; however residual adherent cells 
exhibited intracellular lipid droplets (Figure 3). These data demonstrate that OSA CSCs from all the three 
tumors studied retain differentiation capacity as expected for both normal and tumor stem cells. Moreover, 
we can speculate that, in line with predictable individual differences among primary tumors, OSA1 has a 
more marked mesenchymal phenotype, while OSA2 and OSA3 cells are likely progenitors somewhat more 
committed to osteogenic rather than chondrogenic or adipogenic differentiation.  
 
3.5. Osteosarcoma sphere cells initiate tumors in vivo 
Tumor propagation in vivo is a distinctive hallmark of CSCs (tumor-initiating cells). Thus the gold standard 
method to characterize CSC subpopulations is the tumorigenic assay after serial transplantation in animal 
models. To examine the tumorigenic potential, we tested the ability of the three OSA CSCs and the 
corresponding primary cultures to initiate and support tumor growth in mice. Cells (15x104) from OSA1 CSC, 
OSA2 CSC and OSA3 CSC were injected subcutaneously into immunodeficient mice. To minimize inter-
individual variation and the number of animals to be used, CSCs and non-CSCs obtained from the same OSA 
were injected into the left and right flank of the same mouse, respectively. Tumor development was daily 
monitored, and animals sacrificed when signs of suffering were observed. OSA1, OSA2 and OSA3 non-CSC 
did not develop tumor during the observation period, except for OSA1 which formed a very small tumor 
mass (Figure 4A). In contrast, the CSC counterpart developed tumors, which become visible after about 1 
month from the grafting. Due to OSA CSC tumor development, mice were sacrificed within approximately 
50-60 days (OSA1, 53 days; OSA2, 63 days; OSA 3, 56 days). The weight of xenograft tumors collected at the 
end of the experiments, is reported in Figure 4A. These results confirm that sarcospheres are enriched with 
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CSCs exhibiting enhanced tumorigenic potential and that parenteral cell cultures might contain a too small 
fraction of stem cells, not able to generate tumors.  
 
3.6. Osteosarcoma CSC xenografts recapitulate the original canine tumor histology 
One of the key characteristic of CSCs is the ability to reproduce in xenotransplants the characteristics of the 
tumor from which they were isolated. We therefore compared the histology of tumors developed in mice 
with that of canine original OSA. As shown in Figure 4B, H&E analysis revealed that OSA1, OSA2 and OSA3 
CSC-derived tumors closely reproduced the histotype of the original OSA: tumor osteogenic (OSA1) and 
chondroblastic areas (OSA2 and OSA3) were observed and confirmed the resemblance with original lesion in 
dogs, including the presence of extensive areas of osteoid matrix formed by tumoral osteoblasts or atypical 
cartilage in OSA of chondroblastic pattern. 
To further characterize the phenotype of xenografts , we assessed, by semi-quantitative IHC score (see 
Materials & Methods) the immunoreactivity for relevant markers associated with OSA tumorigenesis and/or 
stemness, including the mesenchymal stem cell markers CD117, the transcription factor Oct-4, STAT3 
frequently overexpressed in human and canine OSA cell lines [67, 68], and the tumor metastasis-associated 
chemokine/receptor pair CXCR4/CXCL12 [69], (Table in Figure 5A). The analysis showed that all markers are 
expressed in mice tumors formed by OSA1, OSA2 and OSA3 CSCs, although at different levels of abundance 
and distribution throughout the tissues (Figure 5B). Following these observations, to verify whether the OSA 
CSC tumor model we developed reflects the general histological and immunohistochemical features of 
canine OSAs, we evaluated the expression of these markers in a series of canine OSAs. To this aim, sections 
of 12 canine OSAs, including the three initial tumors from which we isolated the cell cultures, were studied. 
Animal and tumor characteristics are reported in Supplementary Table 1. The analysis of the expression 
pattern of CXCR4 (11/12 score 1 and 1/12 score 2), CXCL12 (7 score 1 and 5 score 2), Oct4 (9 score 1 and 3 
score 2) and STAT3 (9 score 1 and 2 score 2) showed a marked immunopositivity, although detectable at 
different levels, whereas CD117 (1 score 2, 4 score 1 and 7 score 0) was detected in a lower number of 
samples (5/12). Overall, these data confirm that tumors obtained by CSC xenografts maintain the general 
phenotype of canine OSAs. 
 
3.7. Osteosarcoma CSCs retain tumor-forming potential during serial in vivo transplantation 
Tumorigenicity of OSA CSCs after serial transplantation should be retained or even increased due to in vivo 
enrichment in tumor-initiating cell subpopulation. Since a small tumor was obtained only after xenograft of 
OSA1 cells non enriched in CSCs, we analyzed the tumorigenicity of OSA1 CSC and OSA1 cells isolated from 
first xenografts into new recipient mice. OSA1 cells isolated from mice tumors were re-cultured in stem cell 
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permissive medium (containing EGF and bFGF), confirming that cells from tumors originated from OSA CSC 
can proliferate in vitro as spheroids (data not shown). Xenografted OSA1 not enriched in CSC were collected 
and cultured again in medium with serum. Both cell cultures re-implanted in mice developed tumors (Figure 
6A), which at the sacrifice of animals (after 56 days) were much larger than those developed after the first in 
vivo passage (see Figure 5A), suggesting an increased tumorigenic potential likely induced by an enrichment 
of tumor-initiating CSCs. Importantly, also the cells derived from OSA1 non-CSC (original culture) xenografts, 
which developed very small tumors in the first round of in vivo growth (Figure 5), gave origin to large tumors 
in the second round (Figure 6A), further confirming that the in vivo growth contribute to the selection and 
enrichment in tumor-initiating cells also in cells with initial low tumorigenic potential. Tumors of both first 
and second transplants showed the same histology (data not shown). Comparing immunohistochemistry 
results on sections from first and second injection, we observed that scores of CD117, STAT3 CXCR4 and 
CXCL12 increased, while Oct4 levels did not change in OSA1 non CSC-derived tumors and decreased in OSA1 
CSC xenografts (Figure 6C). Altogether these findings suggest that in vivo growth not only preserves but also 
enhances CSC content within OSA cell population.  
 
3.8. Doxorubicin and cisplatin decrease cell viability of osteosarcoma CSCs  
The sensitivity toward drugs commonly used in clinics (doxorubicin, cisplatin) between OSA CSCs and non-
CSCs, was tested using the MTT cell viability assay. In order to allow a better cellular and biochemical 
evaluation, experiments were performed on short-term monolayer cultures obtained after disaggregation of 
sarcospheres and seeding cells on Matrigel to facilitate temporary adhesion prior drug exposure, that was 
previously reported not interfere with CSC features [18, 57].  
OSA1, OSA2 and OSA3 CSCs, and their respective parental cultures, were treated with increasing 
concentrations of doxorubicin (range 0.03-30 µM) and cisplatin (range (0.3-30 µM) for 48h (Figure 7). Dose-
response curves reported in Figure 7A indicate that doxorubicin caused a concentration-dependent 
reduction of cell viability, in all the three cultures, however very slight differences were observed among CSC 
subsets and original cultures being IC50 values similar (OSA1 CSC 0.8 μM vs. OSA1 1 μM; OSA2 CSC 0.2 μM vs. 
OSA2 0.1 μM; OSA3 CSC 0.2 μM vs. OSA3 0.1 μM) (Figure 7A).  
The cytotoxic effect of cisplatin (Figure 7B) showed the IC50 for OSA2 CSC and OSA3 CSC higher (12.5 μM and 
12.8 μM, respectively) than respective original non-CSCs cells (OSA2 4.3 μM; OSA3 3.1 μM), showing the 
expected increased drug resistance (about 3-4 fold) which characterizes CSCs. On the contrary, OSA1 
parental cells and CSCs exhibited similar dose-response curves and IC50 values (9.2 μM and 9.1 μM, 
respectively) (Figure 7B).  
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3.9. Metformin inhibits survival, self-renewal and proliferation of OSA CSCs, and enhances doxorubicin 
and cisplatin cytotoxicity  
Recent evidence indicates that metformin, an oral hypoglycemic drug, may reduce cell growth and survival 
selectively affecting CSCs in different tumors including OSA [30, 49, 51]. Therefore, we compared sensitivity 
to increasing concentrations of metformin (0.3-30 mM, for 48h) between OSA CSCs and non-stem OSA cells 
(Figure 8A). Metformin reduced cell viability in a dose-dependent manner (about -75% for the highest 
concentration tested), reaching IC50 values of 2.4 mM and 1.8 mM for OSA1 CSC and OSA2 CSC, respectively, 
with a slightly more potent response as compared to non-stem OSA1 and OSA2 that showed IC50 of 7.2 mM 
and 2.2 mM, respectively. Conversely, both OSA3 and OSA3 CSCs showed lower sensitivity to metformin (-
35% viability at 30 mM concentration), with IC50 not evaluable.  
The effect of metformin on stemness and proliferation rate was further detailed only on sensitive OSA CSC 
cultures. In particular, we performed in vitro assays to evaluate the effects of metformin on clonal growth 
ability, measuring the colony-forming efficiency (CFE), as well as testing self-renew potential assessing the 
ability to generate spheroids after serial in vitro passages (Figure 8B-C-D).  
CFE of OSA1 and OSA2 CSCs, was tested using 3 mM metformin, representing a concnetration close to the 
IC50 for both OSA1 and OSA2, to limit the direct cytotoxicity induced by higher concentrations of the drug. 
The evaluation was performed after 14 days of drug exposure to allow non-responsive cells to proliferate 
and generate visible colonies. metformin treatment induced a marked reduction in colony formation as 
compared to control cultures in both OSA1 (CFE 19% vs. 43%) and OSA2 (CFE 1% vs. 29%) (Figure 8B).  
To determine whether metformin impairs self-renewal, we analyzed metformin effect on the ability of OSA 
CSCs to grow as sarcospheres under serum-free medium culturing conditions (using low adhesion plates). 
Within 7 days from the plating OSA1 and OSA2 CSCs formed spheroids that were treated with metformin (3 
mM) for further 5 days: metformin reduced the number of spheres in both cultures as compared to 
untreated cells (Figure 8C). In order to study the long-term effects of metformin on self-renewal ability, 
primary spheres were dissociated into single cells, treated with vehicle or metformin (3 mM for 48h) and 
allowed to grow for further 7 days until formation of secondary spheres. This procedure was repeated for up 
to 6 cycles of dissociation/formation in the presence or absence of metformin, and total cells composing 
spheres were counted: untreated OSA1 CSC and OSA2 CSC showed a constant ability to self-renew at all the 
time points as shown by the observation that cells isolated from spheroids were able to generate new 
sarcospheres with basically the same efficiency even after 6 passages (Figure 8D). Conversely, metformin 
treatment completely impaired self-renewal of OSA1 CSCs that after only two passages were no longer able 
to form new spheroids, and progressively reduced this ability in OSA2 CSCs over passages, only few very 
small sarcospheres present after the last dissociation cycle (Figure 8D).  
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Collectively, these results indicate that metformin significantly inhibited both the growth of primary 
spheroids and sphere generations in OSA1 CSC and OSA2 CSC, suggesting the depletion of the stem 
subpopulation within OSA cultures. 
Metformin was reported to increase CSC sensitivity to standard anti-cancer agents, likely circumventing 
drug resistance [70, 71]. Thus we evaluated whether metformin acts as OSA CSC sensitizer toward the 
cytotoxic effects of doxorubicin and cisplatin. Metformin-sensitive OSA CSCs were exposed to each drug 
alone or to combinations of doxorubicin or cisplatin with metformin. After 48h cell viability was assayed by 
MTT test. Cisplatin- and doxorubicin-induced cytotoxicity was comparably potentiated by co-treatment with 
metformin, in OSA1 and OSA2 CSCs, resulting in approximately 10-40% potentiation of the cytotoxicity of 
both drugs (Figure 9). Quantitative determination of combination effect was evaluated using the Chou-
Talalay’s CI method where CI<1 is index of synergistic activity between the drugs analyzed [60]. We observed 
that for concentrations corresponding to the IC50 values CIs were 0.78 and 0.70 for the association of 
doxorubicin and metformin, and 0.68 for the association of cisplatin and metformin, in OSA2 CSCs, 
respectively. These results support that the administration of metformin induces a moderate synergism with 
both cytotoxic drugs.  
 
4. DISCUSSION  
OSA is a mesenchymal malignancy of bones that shares genetic and molecular alterations, histopathology, 
frequency of microscopic metastases at diagnosis, and clinical behavior in humans and dogs [31]. 
Conventional chemotherapeutic agents (including cisplatin and doxorubicin) prolong OSA patient’s lifespan 
without increasing survival rate which remains poor due to development of microscopic or diffuse 
chemotherapy-resistant metastases [72]. Therefore, search of alterative adjuvant therapies for improving 
management of OSA progression is clinically warranted. CSC model proposes that a subset of tumorigenic 
cells possessong stem-like properties drive tumor initiation, metastasis, drug resistance, and recurrence. This 
model gained increasing relevance in many solid cancers, including OSA, likely representing a biological 
correlate for the aggressive clinical behavior of this tumor. Isolation and characterization of CSCs represents 
a key step to study OSA pathogenesis and biology and develop more efficacious therapies. In particular, the 
identification of human and canine CSCs derived from surgical tissues of OSA contributed to clarify their 
stem-like features and, prospectively, to develop targeted drugs to eradicate this cell subpopulation [30, 73, 
74]. In the current study we assessed the biological and pharmacological properties of three patient-derived 
canine OSA cultures.  
All cultures showed ability to grow as spheroids when grown in growth factor-containing medium, forming 
either compact spheres or loose aggregates, which retained self-renewal ability for multiple passages. 
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Spherogenesis has been indeed exploited as one of the methods to identify CSCs in vitro, reflecting the 
capacity of cells endowed with stem-like properties to grow under non-adherent conditions. In particular, 
spherogenesis was used to identify CSC subsets cell lines and tumors by self-renew ability in human and 
canine OSA [11, 38, 74], as well as in several other cancer types [75]. In vitro self-renewal properties is not 
exclusive for CSCs [76], thus in vivo tumorigenicity of OSA CSC cultures after various initial enrichment 
techniques (expression and activity of aldehyde dehydrogenase, ALDH, side population isolation, 
spherogenesis, CD133, CD117 (c-kit), Stro-1 expression) [77-80], was also reported, representing the crucial 
method to validate putative CSCs. In particular, the serial transplantation of low number of CSC candidates 
into immunocompromised mice (tumor-initiating activity) is, to date, considered the only definitive prove of 
the presence of CSCs in a given culture. We report that cells isolated from canine primary OSA, and grown in 
vitro as sarcospheres, possess high tumorigenic capacity in vivo. OSA1, OSA2 and OSA3 cultures 
xenotransplanted in mice, achieved 100% engraftment and developed tumors recapitulate the original 
tumor histology. Mouse xenograft generation has been obtained at low number of cells (15x104), as 
compared to other studies (e.g. 3x106 cells of human osteosarcoma 3AB-OS CSCs isolated from human 
osteosarcoma MG63 cells, [81], or a subset of OSA cells sorted from OS99-1 cell line for ALDH enzymatic 
activity, in which tumor formation was highly dependent on the number of injected cells, likely suggesting 
that tumorigenic cells were extremely rare [82]). The tumor-initiating ability of sarcosphere cells, also 
considering that the parental primary cultures were not able to consistently give rise to tumors in the same 
experimental conditions, definitely demonstrates the stem nature of our OSA cultures.  
Moreover, cells obtained from excised xenograft tumors re-cultured in vitro exhibited functional 
characteristics such as spherogenesis and proliferation confirming stem-cell like properties of these OSA CSC 
cultures. Second transplant of OSA1 CSCs successfully engraft and initiate tumor in new recipient mice, 
preserving the original histopathologic appearance of original canine OSA, also observed in the primary 
xenografts, indicating that the in vitro experimental conditions we adopted do not impair tumor-initiating 
potential of these cells. OSA1 non-CSCs derived from primary xenograft tumors formed secondary 
neoplasms with a higher efficiency than the first injection (in which only small tumors developed) suggesting 
that in vivo growth favors the selection of CSC-like cells, as also shown by the increased detection of stem 
cell markers in histological preparations from the second injection.  
The observation that the first injection of non-CSCs failed to form consistent tumors as done by CSCs, 
suggests that sarcosphere cells are essentially different from their original counterparts, and initial OSA 
primary cultures contain a limited number of CSC cells within the large number of non-CSCs; conversely, 
CSCs are enriched in vitro by stem-permissive culture conditions and in vivo by mice transplantation, and can 
be found in both conditions after the second mouse transplant. By enriching the cultures in OSA CSC 
subpopulation, xenografts enhance the aggressive and self-renewing potential of these cells, and amplify the 
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proportion of cells expressing proteins able to sustain tumor growth and stemness (i.e. Oct4, CD117, STAT3, 
CXCR4, CXCL12). The differential tumor-initiating ability between CSCs and non-stem tumor cells was 
previously reported, nevertheless a direct confrontation between the two populations derived from the 
same primary tumor was rarely performed: Murase et al. detected higher tumorigenic ability of sorted side 
population cells from the bone malignant fibrous histiocytoma cell line MFH2003 compared to the main 
population cells [78]. Mesenchymal tumor (1 osteosarcoma, and 2 malignant fibrous histocytomas, 1 
synovial sarcoma) transplantation into NOD/SCID mice comprising only showed that higher frequency 
tumors were generated with smaller numbers of side population cells  as compared with main population 
cells [83]. 
Although a definitive panel of antigens unequivocally identifying CSCs in OSA and other solid cancers is not 
available [84], we combined tumorigenic and spherogenic activities with the analysis of the expression of 
some stem-related markers, to assess changes in CSC content after in vivo growth. We show the 
concomitant expression of CD133, Oct4, and Sox2 in OSA spheroids, suggestive of stem-cell like properties in 
tumor cells [79, 85, 86], including canine OSA [74, 87]. In particular, CD133 expression has been correlated 
with the gain of tumorigenic activity by OSA cells [80], although it has to be remarked that both CD133-
positive and -negative cells are able to propagate tumors in vivo [88, 89]. On the whole, these results 
support that a combination of CD133+ with other pluripotency factors characterize the stem-like phenotype 
of OSA CSCs.  
CSCs are also responsible for the formation of metastasis. Among proliferation- and metastasis-associated 
proteins in CSCs, the cytokine CXCL12 and its receptor CXCR4 contribute to bone sarcoma progression [90], 
in which the metastatic diffusion represents a major life-limiting factor for both humans and dogs. Few 
studies explored the biological relevance of the CXCL12/CXCR4 axis in canine OSA [91], showing  high 
expression similarly to other canine solid tumors [55]. In the present study, CXCL12/CXCR4 expression within 
sarcospheres well-matches with their diffuse detection in tumor xenografts and original OSA tissues of the 
corresponding dogs (see Tables), suggesting that the regulation of CSC invasive behavior by this chemokine 
system involve autocrine/paracrine activity besides the chemokinergic stimuli produced by tumor 
microenvironment.  
The complexity of OSA CSC characterization also resides in the originating cell types: mesenchymal cells are 
likely one of the cell populations which drive OSA development [13], since these cells are involved in normal 
bone formation by differentiation into osteoblasts. This implies a high mesenchymal differentiating capacity 
of OSA CSCs, allowing the generation of adipocytes, chondrocytes. We show that canine OSA sarcosphere 
cells possess multipotency, with OSA1 CSCs able to differentiate in all the three lineages, and OSA2 and 
OSA3 CSCs showing higher propensity to differentiate into osteoblasts than chondrocytes and adypocytes. 
Overall these findings suggest that OSA CSCs retain a different degree of mesenchymal features, correlated 
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with the stage of differentiation of parental cells or the histologic subtype, highlighting that intrinsic 
heterogeneity of individual tumors may reflect the diverse properties of CSCs. The mesenchymal phenotype 
of canine OSA CSCs is also suggested by vimentin expression, the most widely accepted mesenchymal 
marker that is down-regulated in fully differentiated osteoblasts [92]. Moreover, all OSA sarcosphere cells 
also express osterix, an early/middle osteogenic regulator, which indicates that canine OSA CSCs are likely 
derived by osteogenic progenitors [93]. The presence of scattered positive cells for type 1 collagen, a late 
osteogenic marker, in OSA1 and OSA2 spheroids, further confirms the predominance of OSA cells not 
terminally differentiated. We therefore propose that CSC cultures isolated form the three OSAs are 
composed of tumor-initiating cells at distinct differentiation stage, but showing a common, although not 
identical, phenotype. 
CSCs are responsible of drug resistance and tumor recurrence [94]; while the prediction of treatment 
response in aggressive tumors is still an unmet need, cytotoxicity in vitro assays routinely performed on 
established cancer cell lines or, rarely, on primary cultures deriving from bulk tumor cells, still have a low 
translational value. In particular, since these models neglect the chemo-sensitivity profile of the minority CSC 
population which may significantly differ from the other tumor cell populations. Indeed, although chemo-
sensitivity is not a defining feature for CSC isolation, it could be considered as a relevant CSC property [95]. 
This issue is even more critical in OSA whose lethality is mainly due to the early onset of metastases and drug 
resistance. In our study, IC50 calculations of doxorubicin and cisplatin cytotoxicity, the chemotherapy 
regimen used in both humans and dogs, showed that canine OSA CSCs are generally less sensitive than the 
corresponding parental cells, although the difference was higher for cisplatin than doxorubicin. Previous 
studies reported that CSCs isolated from OSA cell lines are more resistant to doxorubicin [96]. The 
originating cell type may contribute to the drug response of CSCs (e.g. CSCs isolated from established, long-
term culture cell lines tend to be more resistant to drugs, because of the more differentiated phenotype or 
adaptation to in vitro culture conditions) as also observed in glioblastoma CSCs [97]. On the contrary, our 
CSC cultures exhibited a marked resistance to cisplatin, as observed in stem-like populations from human 
sarcoma cell lines [96], and in agreement with the observation that cisplatin-resistant OSA cells exhibited 
stem-like characteristics both in vitro and in vivo, which are not observed in cisplatin-responsive cells [98].  
Repositioning of metformin as antitumor drug [40] was related to the ability to preferentially affect CSC 
proliferation and survival [45-47]. AMPK activation and the consequent inhibition of mTOR signaling was the 
first proposed mechanism of metformin activity on CSCs [99], but several AMPK-independent pathways 
contributing to its antitumor activity have been also suggested [45, 100]. Here we report that metformin 
significantly impairs survival and spherogenesis of canine OSA1 and OSA2 CSCs, indicating, besides an 
antiproliferative effect, also a direct inhibition of self-renewal. Similar results were obtained in stem-like cells 
derived from the MG63 cell line, canine mammary carcinoma, human hepatocellular carcinoma or human 
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glioblastoma [28, 47, 49, 101]. Unexpectedly, OSA3 CSCs were less sensitive to metformin. We do not have 
an explanation for this difference, but it is noteworthy that these individual pharmacological diversities are 
evidenced only using cells isolated from primary tumors, which thus should represent the more reliable 
model to translate preclinical data to clinical trials. Differently from other tumor cells [47], parental OSA1 
and OSA2 were only slightly less sensitive to metformin than respective CSCs. The high level of intra-tumor 
heterogeneity of OSA and plasticity of CSCs which dynamically can undergo differentiation and 
dedifferentiation [102], highlights how ideal therapeutic compounds or drug combination must suppress the 
survival and proliferation of both CSCs and non-CSCs, and metformin, targeting both cancer cell subsets, 
prospectively provides a rationale for novel therapeutic options against cancer progression. The chemo-
sensitizing/adjuvant role of metformin has been postulated in various cancers however, beside preliminary 
encouraging data, its impact on tumor response is still under investigation [103]. In OSA cells, metformin co-
treatment enhanced anti-proliferative and pro-apoptotic effects of trichostatin A and simvastatin [104, 105]. 
In our experimental model, the treatment with metformin sensitizes OSA1 and OSA2 CSCs to cisplatin and 
doxorubicin, as also reported in stem-like cells derived from human OSA cell lines [50, 51]. Thus these data 
support the development of novel clinical trials in which the adjuvant activity of metformin on cytotoxic drug 
activity may represent a novel therapeutic approach for the treatment of OSA. 
5. CONCLUSIONS 
In summary, we demonstrate here that OSA naturally-occurring in dogs contain tumorigenic stem-like cells 
with distinct phenotypes from the non-tumorigenic cells composing the tumor mass. These peculiar 
features, including the inter-tumor heterogeneity, are preserved in long-term culture in vitro and determine 
distinct biological behaviors in term of stem properties and response to conventional drugs, but are 
reconciled in the common essential ability to recapitulate the original tumor in vivo. Metformin suppresses 
viability of OSA CSC and parental cells in vitro, and combination treatment with metformin and conventional 
drugs improve cytotoxic drug response, suppressing both CSC self-renewal and proliferation. Conceivably 
results obtained in canine OSA support their relevance in veterinary oncology and serve as preclinical basis 
for future human therapy strategies. 
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FIGURE LEGENDS 
FIGURE 1.  Characterization of canine OSA cultures enriched in cancer stem cells.  
A) Morphological appearance of OSA1, OSA2 and OSA3 primary cultures. B-C) Phase-contrast 
microphotographs of sarcosphere formation observed after 7 days of culture in OSA1, OSA2 and OSA3 cells 
grown in serum-free medium (OSA CSC). D) Immunocytofluorescence assessment of osteogenic lineage 
markers in OSA sarcospheres. Analysis of the expression of osterix and type I collagen, which appear in cells 
committed to osteogenic lineage, vimentin, which regulates osteoblast differentiation, and osteonectin, up-
regulated by osterix and generally used as later marker of differentiated osteoblasts.  Photomicrographs 
represent merged images (green: marker-positive cells; blue:  DAPI counterstained nuclei). Scale bars: 
50m. 
 
FIGURE 2. Immunocytofluorescence assessment of stem markers in OSA sarcospheres 
Analysis of the expression of markers commonly used to identify cancer stem cells (CD133, Sox2, Oct4, 
CXCR4 and CXCL12) in OSA sarcosphere cells (CSCs) by fluorescence microscopy. Photomicrographs 
represent merged images (green: marker-positive cells; blue:  DAPI counterstained nuclei). Scale bars: 
50m. 
 
FIGURE 3 Analysis of the pluripotency of OSA sarcosphere cells: differentiation into osteoblasts, 
chondrocytes and adipocytes. 
Appearance of monolayer culture obtained by shifting OSA sarcosphere cells (CSCs) from the stem-
permissive growth factor medium to serum-containing medium. 
OSA CSCs were induced to differentiate into osteoblasts, chondrocytes or adipocytes, using appropriate 
defined media, and differentiation ability was assessed by specific staining: 
-Alizarin Red S staining highlights extracellular calcium deposits indicating osteogenic differentiation.  
-Alcian Blue staining indicates proteoglycan synthesis forming cartilage extracellular matrix by chondrocytes.  
-Oil Red O stains cytoplasmic lipid vesicles in adypocytes.  
Representative microphotographs are shown from independently performed experiments.  
 
FIGURE 4. OSA sarcosphere cells are tumorigenic in vivo and xenografts recapitulate the original canine 
tumor  
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A) OSA1, OSA2 and OSA3 primary cultures and sarcosphere cells grown in stem conditions (OSA CSCs) were 
xenografted in immunodeficient mice, and tumor development was monitored. After animal sacrifice tumors 
were excised and weighted. Mean weights ± s.d. are reported in histograms.  
B) Histopathologic examination of mice tumors: representative H&E staining showing that xenografts 
obtained from OSA1, OSA 1 CSC, OSA2 CSC and OSA3 CSC, recapitulate histological characteristics of the 
corresponding original canine tumor, as evaluated on post-surgical samples formalin-fixed, paraffin-
embedded tissue sections.  
 
FIGURE 5. Osteosarcoma CSC xenografts recapitulate the original canine tumor marker expression. 
A) Immunoistochemical (IHC) scores indicating the intensity and distribution of immunopositive labellling for 
CD117, Oct4, STAT3, CXCR4 and CXCL12 in the original canine OSA and corresponding OSA CSC xenografts. 
B) Representative images of antibody localization done using horseradish peroxidase: brown staining 
indicates the presence of the specific antigen. Sections were counterstained with Mayer's haematoxylin 
(blue). Negative controls (Neg) were run in parallel by omitting the primary antibody and by using 
rabbit/mouse IgG.  
FIGURE 6. OSA1 CSCs exhibit enriched tumor-forming ability in secondary xenografts. 
A) Single cell suspension isolated by dissociation of excised xenografts formed by OSA1 and OSA CSC cells, 
were grown under stem conditions as sarcospheres, and subsequently re-injected into new recipient mice. 
Secondary tumor initiation and development was monitored and mean weights are reported in the 
histograms ± s.d.  
B) Variation of IHC scores (0=negative; 1=low positivity; 2= positivity; 3=high positivity) for CD117, Oct4, 
STAT3, CXCR4 and CXCL12 among tumors tissues derived from first (OSA1 CSC 1st) and second injection 
(OSA1 CSC 2nd). 
 
FIGURE 7. Doxorubicin and cisplatin impair cell viability of osteosarcoma CSCs.  
Sensitivity to doxorubicin and cisplatin was evaluated in OSA CSCs in the same condition (2D, monolayer on 
Matrigel) as the parental OSA cells, after dissociation of sarcospheres into single cells, seeded in a 96-well 
plate, and incubated for 24h. Cells were treated with increasing concentrations of doxorubicin (A) and 
cisplatin (B) or vehicle for 48h (the same condition applied for the parental cells) and cell viability was 
measured by MTT assay.  Dose-response curves represent mean ± s.e.m. from three independent 
experiments each performed in quadruplicate.  
 
FIGURE 8. Metformin inhibits the cell viability and self-renewal of osteosarcoma CSCs. 
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A) Sensitivity to metformin was evaluated in parental OSA cells and OSA CSCs (cultured as monolayer on 
Matrigel), seeded in a 96-well plates for 24h prior to the treatment with the drug or vehicle for 48h. Cell 
viability was measured by MTT assay.  Dose-response curves represent mean ± s.e.m. from three 
independent experiments each performed in quadruplicate.  
B) Colony forming efficiency (CFE) in OSA1 CSC and OSA2 CSC was evaluated in the presence of 3 mM 
metformin or vehicle: CFE (%) was significantly lower in treated cells vs. controls (* p= 0.05; ** p =0.01,). 
Representative photographs of colonies are reported. Data represent mean ± s.e.m. 
C). Sarcospheres formed by OSA1 CSC and OSA2 CSC were treated with 3 mM metformin or vehicle, and 
counted after 5 days of treatment:  the number of sarcospheres was significantly reduced in treated cells vs. 
controls (* p= 0.05). Data represent mean ± s.e.m. 
D) Sphere-forming of OSA1 CSC (left panel) and OSA2 CSC (right panel) capacity was evaluated in the 
absence or presence of metformin (3mM): every 7 days sarcospheres were dissociated to single cell 
suspension and cells were counted and re-plated in fresh medium in the same. The number of viable cells 
composing spheres was counted for up to six passages. Data represent mean ± s.e.m. (* p= 0.05; ** p =0.01; 
***P=0.001). Metformin impaired self-renewal of OSA1 CSCs after two passages, and progressively and 
reduced this ability in OSA2 CSCs. 
 
FIGURE 9. Cisplatin- and doxorubicin-induced cytotoxicity is enhanced by co-treatment with metformin. 
OSA1 CSC and OSA2 CSC were treated with doxorubicin or cisplatin alone or as combination with metformin, 
(at concentrations corresponding to the IC50 for each drug) or vehicle, for 48h. Cell viability was evaluated by 
MTT assay. Data represent the mean ± s.e.m., as % of controls taken as 100% (* p= 0.05; ** p =0.01; 
***P=0.001). 
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